Ki67 proliferation index in medullary thyroid carcinoma: a comparative study of multiple counting methods and validation of image analysis and deep learning platforms.

Ki67 proliferation index deep learning grade machine learning medullary thyroid carcinoma

Journal

Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136

Informations de publication

Date de publication:
Dec 2023
Historique:
revised: 16 08 2023
received: 21 06 2023
accepted: 18 08 2023
medline: 7 11 2023
pubmed: 14 9 2023
entrez: 14 9 2023
Statut: ppublish

Résumé

The International Medullary Thyroid Carcinoma Grading System, introduced in 2022, mandates evaluation of the Ki67 proliferation index to assign a histological grade for medullary thyroid carcinoma. However, manual counting remains a tedious and time-consuming task. We aimed to evaluate the performance of three other counting techniques for the Ki67 index, eyeballing by a trained experienced investigator, a machine learning-based deep learning algorithm (DeepLIIF) and an image analysis software with internal thresholding compared to the gold standard manual counting in a large cohort of 260 primarily resected medullary thyroid carcinoma. The Ki67 proliferation index generated by all three methods correlate near-perfectly with the manual Ki67 index, with kappa values ranging from 0.884 to 0.979 and interclass correlation coefficients ranging from 0.969 to 0.983. Discrepant Ki67 results were only observed in cases with borderline manual Ki67 readings, ranging from 3 to 7%. Medullary thyroid carcinomas with a high Ki67 index (≥ 5%) determined using any of the four methods were associated with significantly decreased disease-specific survival and distant metastasis-free survival. We herein validate a machine learning-based deep-learning platform and an image analysis software with internal thresholding to generate accurate automatic Ki67 proliferation indices in medullary thyroid carcinoma. Manual Ki67 count remains useful when facing a tumour with a borderline Ki67 proliferation index of 3-7%. In daily practice, validation of alternative evaluation methods for the Ki67 index in MTC is required prior to implementation.

Identifiants

pubmed: 37706239
doi: 10.1111/his.15048
doi:

Substances chimiques

Ki-67 Antigen 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

981-988

Subventions

Organisme : Cancer Center Support Grant of the National Institutes of Health/National Cancer Institute
ID : P30CA008748
Organisme : Italian Government Ministry of Health,
ID : RF-2011-02350857
Organisme : Cancer Tissue and Pathology, Emory Integrated Genomics Core (EIGC)
Organisme : Emory Integrated Computational Core (EICC),
Organisme : Winship Cancer Institute of Emory University and NIH/NCI
ID : P30CA138292
Organisme : National Center for Georgia Clinical and Translational Science Alliance of the National Institutes of Health
ID : UL1TR002378

Informations de copyright

© 2023 John Wiley & Sons Ltd.

Références

Barletta JA, Nosé V, Sadow PM. Genomics and epigenomics of medullary thyroid carcinoma: from sporadic disease to familial manifestations. Endocr. Pathol. 2021; 32; 35-43.
Xu B, Fuchs TL, Ahmadi S et al. International medullary thyroid carcinoma grading system: a validated grading system for medullary thyroid carcinoma. J. Clin. Oncol. 2022; 40; 96-104.
Vissio E, Maletta F, Fissore J et al. External validation of three available grading systems for medullary thyroid carcinoma in a single institution cohort. Endocr. Pathol. 2022; 33; 359-370.
Williams JF, Zhao M, Najdawi F et al. Grading of medullary thyroid carcinoma: an interobserver reproducibility study. Endocr. Pathol. 2022; 33; 371-377.
La Rosa S. Diagnostic, prognostic, and predictive role of ki67 proliferative index in neuroendocrine and endocrine neoplasms: past, present, and future. Endocr. Pathol. 2023; 34; 79-97.
He Q, Liu Y, Pan F et al. Unsupervised domain adaptive tumor region recognition for ki67 automated assisted quantification. Int. J. Comput. Assist. Radiol. Surg. 2023; 18; 629-640.
Fulawka L, Blaszczyk J, Tabakov M, Halon A. Assessment of ki-67 proliferation index with deep learning in dcis (ductal carcinoma in situ). Sci. Rep. 2022; 12; 3166.
Feng M, Deng Y, Yang L et al. Automated quantitative analysis of ki-67 staining and he images recognition and registration based on whole tissue sections in breast carcinoma. Diagn. Pathol. 2020; 15; 65.
Niazi MKK, Tavolara TE, Arole V, Hartman DJ, Pantanowitz L, Gurcan MN. Identifying tumor in pancreatic neuroendocrine neoplasms from ki67 images using transfer learning. PLoS ONE 2018; 13; e0195621.
Reid MD, Bagci P, Ohike N et al. Calculation of the ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies. Mod. Pathol. 2016; 29; 93.
Tang LH, Gonen M, Hedvat C, Modlin IM, Klimstra DS. Objective quantification of the ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods. Am. J. Surg. Pathol. 2012; 36; 1761-1770.
Xu B, Viswanathan K, Lubin D et al. Ret and ras mutations in medullary thyroid carcinoma (MTC) and their impact on histologic grade, tumor characteristics, and clinical outcome: an international multicentric study of 289 patients. In USCAP 2023 Annual Meeting. New Orleans, LA, USA: USCAP, 2023.
Bankhead P, Loughrey MB, Fernández JA et al. Qupath: open source software for digital pathology image analysis. Sci. Rep. 2017; 7; 16878.
Ghahremani P, Marino J, Dodds R, Nadeem S. Deepliif: an online platform for quantification of clinical pathology slides. Proc. IEEE Comput. Soc. Conf. Comput. Vis. Pattern Recognit. 2022; 2022; 21399-21405.
Ghahremani P, Li Y, Kaufman A et al. Deep learning-inferred multiplex immunofluorescence for immunohistochemical image quantification. Nat Mach Intell 2022; 4; 401-412.
Krystel-Whittemore M, Wen H, Giri D, Kuba M, Brogi E, Hanna MG. Quantification of ki67 in breast cancer using image analysis software: a validation study. USCAP Annual Meeting 2022. Los Angeles, CA, USA. Mod. Pathol. 2022; 3; 1163-1210.
Behrman DB, Lubin DJ, Magliocca K, Shi Q, Viswanathan K. Exploration of digital image analysis for ki67 quantification in the grading of medullary thyroid carcinoma: a pilot study with 85 cases. Head Neck Pathol. 2023. https://doi.org.10.1007/s12105-023-01564-8
Burgart LJ, Chopp WV, Jain D. Protocol for the examination of specimens from patients with tumors of the endocrine pancreas. 2021.
Tisell LE, Oden A, Muth A et al. The ki67 index a prognostic marker in medullary thyroid carcinoma. Br. J. Cancer 2003; 89; 2093-2097.
Fuchs TL, Nassour AJ, Glover A et al. A proposed grading scheme for medullary thyroid carcinoma based on proliferative activity (ki-67 and mitotic count) and coagulative necrosis. Am. J. Surg. Pathol. 2020; 44; 1419-1428.

Auteurs

Saad Nadeem (S)

Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Matthew G Hanna (MG)

Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Kartik Viswanathan (K)

Department of Pathology, Emory University Hospital Midtown, Atlanta, GA, USA.

Joseph Marino (J)

Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Mahsa Ahadi (M)

Royal North Shore Hospital and Northern Clinical School, Sydney Medical School, University of Sydney, Sydney, Australia.
Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards, Australia.
NSW Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, St Leonards, Australia.

Bayan Alzumaili (B)

Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Mohamed-Amine Bani (MA)

Medical Pathology and Biology Department, Gustave Roussy Campus Cancer, Villejuif, France.

Federico Chiarucci (F)

Department of Medical and Surgical Sciences (DIMEC), University of Bologna Medical Center, Bologna, Italy.
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Angela Chou (A)

Royal North Shore Hospital and Northern Clinical School, Sydney Medical School, University of Sydney, Sydney, Australia.
Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards, Australia.
NSW Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, St Leonards, Australia.

Antonio De Leo (A)

Department of Medical and Surgical Sciences (DIMEC), University of Bologna Medical Center, Bologna, Italy.
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Talia L Fuchs (TL)

Royal North Shore Hospital and Northern Clinical School, Sydney Medical School, University of Sydney, Sydney, Australia.
Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards, Australia.
NSW Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, St Leonards, Australia.

Daniel J Lubin (DJ)

Department of Pathology, Emory University Hospital Midtown, Atlanta, GA, USA.

Catherine Luxford (C)

Royal North Shore Hospital and Northern Clinical School, Sydney Medical School, University of Sydney, Sydney, Australia.
Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards, Australia.
NSW Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, St Leonards, Australia.

Kelly Magliocca (K)

Department of Pathology, Emory University Hospital Midtown, Atlanta, GA, USA.

Germán Martinez (G)

Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Qiuying Shi (Q)

Department of Pathology, Emory University Hospital Midtown, Atlanta, GA, USA.

Stan Sidhu (S)

Royal North Shore Hospital and Northern Clinical School, Sydney Medical School, University of Sydney, Sydney, Australia.
Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards, Australia.
NSW Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, St Leonards, Australia.

Abir Al Ghuzlan (A)

Medical Pathology and Biology Department, Gustave Roussy Campus Cancer, Villejuif, France.

Anthony J Gill (AJ)

Royal North Shore Hospital and Northern Clinical School, Sydney Medical School, University of Sydney, Sydney, Australia.
Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards, Australia.
NSW Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, St Leonards, Australia.

Giovanni Tallini (G)

Department of Medical and Surgical Sciences (DIMEC), University of Bologna Medical Center, Bologna, Italy.
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Ronald Ghossein (R)

Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Bin Xu (B)

Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH